Glycoconjugate vaccines provide highly effective protection against disease. But so far, they have been developed by time-consuming trial and error. Now, an EU-funded project is building up knowledge and skills to better design these vaccines in a bid to bring treatments to patients faster and keep European pharmaceutical innovation competitive.from EUROPA - Syndicated Research News Feed https://ift.tt/2GUxCu6
via IFTTT
No comments:
Post a Comment